nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—CHRM3—ureter—prostate cancer	0.0454	0.535	CbGeAlD
Glycopyrrolate—CHRM5—epithelium—prostate cancer	0.00696	0.082	CbGeAlD
Glycopyrrolate—CHRM2—prostate gland—prostate cancer	0.0065	0.0766	CbGeAlD
Glycopyrrolate—CHRM1—prostate gland—prostate cancer	0.00592	0.0697	CbGeAlD
Glycopyrrolate—CHRM4—testis—prostate cancer	0.00534	0.0629	CbGeAlD
Glycopyrrolate—CHRM3—prostate gland—prostate cancer	0.0053	0.0624	CbGeAlD
Glycopyrrolate—CHRM3—renal system—prostate cancer	0.00361	0.0425	CbGeAlD
Glycopyrrolate—CHRM3—urethra—prostate cancer	0.00355	0.0418	CbGeAlD
Glycopyrrolate—CHRM3—testis—prostate cancer	0.00233	0.0275	CbGeAlD
Glycopyrrolate—Oxybutynin—CYP3A5—prostate cancer	0.000378	0.698	CrCbGaD
Glycopyrrolate—Pneumonia—Epirubicin—prostate cancer	0.000326	0.000444	CcSEcCtD
Glycopyrrolate—Mental disorder—Prednisone—prostate cancer	0.000326	0.000444	CcSEcCtD
Glycopyrrolate—Convulsion—Docetaxel—prostate cancer	0.000325	0.000443	CcSEcCtD
Glycopyrrolate—Hypertension—Docetaxel—prostate cancer	0.000324	0.000442	CcSEcCtD
Glycopyrrolate—Drowsiness—Epirubicin—prostate cancer	0.000324	0.000442	CcSEcCtD
Glycopyrrolate—Infestation NOS—Epirubicin—prostate cancer	0.000324	0.000442	CcSEcCtD
Glycopyrrolate—Infestation—Epirubicin—prostate cancer	0.000324	0.000442	CcSEcCtD
Glycopyrrolate—Erythema—Prednisone—prostate cancer	0.000324	0.000441	CcSEcCtD
Glycopyrrolate—Malnutrition—Prednisone—prostate cancer	0.000324	0.000441	CcSEcCtD
Glycopyrrolate—Palpitations—Capecitabine—prostate cancer	0.000321	0.000438	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Etoposide—prostate cancer	0.000318	0.000434	CcSEcCtD
Glycopyrrolate—Asthenia—Mitoxantrone—prostate cancer	0.000318	0.000433	CcSEcCtD
Glycopyrrolate—Fatigue—Etoposide—prostate cancer	0.000318	0.000433	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000318	0.000433	CcSEcCtD
Glycopyrrolate—Constipation—Etoposide—prostate cancer	0.000315	0.00043	CcSEcCtD
Glycopyrrolate—Pain—Etoposide—prostate cancer	0.000315	0.00043	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Epirubicin—prostate cancer	0.000315	0.000429	CcSEcCtD
Glycopyrrolate—Dizziness—Estradiol—prostate cancer	0.000315	0.000429	CcSEcCtD
Glycopyrrolate—Dysuria—Doxorubicin—prostate cancer	0.000315	0.000429	CcSEcCtD
Glycopyrrolate—Hypertension—Capecitabine—prostate cancer	0.000314	0.000428	CcSEcCtD
Glycopyrrolate—Dry mouth—Docetaxel—prostate cancer	0.000313	0.000426	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000313	0.000426	CcSEcCtD
Glycopyrrolate—Sweating—Epirubicin—prostate cancer	0.000311	0.000423	CcSEcCtD
Glycopyrrolate—Confusional state—Docetaxel—prostate cancer	0.000309	0.000421	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000307	0.000419	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Docetaxel—prostate cancer	0.000307	0.000418	CcSEcCtD
Glycopyrrolate—Oedema—Docetaxel—prostate cancer	0.000307	0.000418	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—prostate cancer	0.000306	0.000417	CcSEcCtD
Glycopyrrolate—Vision blurred—Prednisone—prostate cancer	0.000305	0.000416	CcSEcCtD
Glycopyrrolate—Infection—Docetaxel—prostate cancer	0.000305	0.000415	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—prostate cancer	0.000304	0.000414	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Etoposide—prostate cancer	0.000304	0.000414	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—prostate cancer	0.000303	0.000413	CcSEcCtD
Glycopyrrolate—Dry mouth—Capecitabine—prostate cancer	0.000303	0.000413	CcSEcCtD
Glycopyrrolate—Vomiting—Estradiol—prostate cancer	0.000303	0.000412	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—prostate cancer	0.000302	0.000411	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Etoposide—prostate cancer	0.000302	0.000411	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Docetaxel—prostate cancer	0.000301	0.00041	CcSEcCtD
Glycopyrrolate—Rash—Estradiol—prostate cancer	0.0003	0.000409	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—prostate cancer	0.0003	0.000409	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—prostate cancer	0.0003	0.000409	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—prostate cancer	0.0003	0.000409	CcSEcCtD
Glycopyrrolate—Dermatitis—Estradiol—prostate cancer	0.0003	0.000408	CcSEcCtD
Glycopyrrolate—Confusional state—Capecitabine—prostate cancer	0.000299	0.000408	CcSEcCtD
Glycopyrrolate—Tachycardia—Docetaxel—prostate cancer	0.000299	0.000408	CcSEcCtD
Glycopyrrolate—Headache—Estradiol—prostate cancer	0.000298	0.000406	CcSEcCtD
Glycopyrrolate—Skin disorder—Docetaxel—prostate cancer	0.000298	0.000406	CcSEcCtD
Glycopyrrolate—Agitation—Prednisone—prostate cancer	0.000298	0.000406	CcSEcCtD
Glycopyrrolate—Oedema—Capecitabine—prostate cancer	0.000297	0.000404	CcSEcCtD
Glycopyrrolate—Infection—Capecitabine—prostate cancer	0.000295	0.000402	CcSEcCtD
Glycopyrrolate—Urticaria—Etoposide—prostate cancer	0.000293	0.000399	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—prostate cancer	0.000292	0.000398	CcSEcCtD
Glycopyrrolate—Abdominal pain—Etoposide—prostate cancer	0.000292	0.000397	CcSEcCtD
Glycopyrrolate—Body temperature increased—Etoposide—prostate cancer	0.000292	0.000397	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—prostate cancer	0.000292	0.000397	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Capecitabine—prostate cancer	0.000291	0.000397	CcSEcCtD
Glycopyrrolate—Tachycardia—Capecitabine—prostate cancer	0.00029	0.000395	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—prostate cancer	0.00029	0.000395	CcSEcCtD
Glycopyrrolate—Skin disorder—Capecitabine—prostate cancer	0.000288	0.000393	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—prostate cancer	0.000288	0.000392	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—prostate cancer	0.000287	0.000392	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Capecitabine—prostate cancer	0.000287	0.000391	CcSEcCtD
Glycopyrrolate—Hypotension—Docetaxel—prostate cancer	0.000286	0.00039	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—prostate cancer	0.000286	0.00039	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—prostate cancer	0.000285	0.000389	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—prostate cancer	0.000283	0.000385	CcSEcCtD
Glycopyrrolate—Nausea—Estradiol—prostate cancer	0.000283	0.000385	CcSEcCtD
Glycopyrrolate—Vomiting—Mitoxantrone—prostate cancer	0.000282	0.000384	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—prostate cancer	0.000281	0.000383	CcSEcCtD
Glycopyrrolate—Convulsion—Prednisone—prostate cancer	0.000281	0.000382	CcSEcCtD
Glycopyrrolate—Hypertension—Prednisone—prostate cancer	0.00028	0.000381	CcSEcCtD
Glycopyrrolate—Rash—Mitoxantrone—prostate cancer	0.00028	0.000381	CcSEcCtD
Glycopyrrolate—Dermatitis—Mitoxantrone—prostate cancer	0.000279	0.000381	CcSEcCtD
Glycopyrrolate—Headache—Mitoxantrone—prostate cancer	0.000278	0.000379	CcSEcCtD
Glycopyrrolate—Hypotension—Capecitabine—prostate cancer	0.000277	0.000378	CcSEcCtD
Glycopyrrolate—Insomnia—Docetaxel—prostate cancer	0.000277	0.000378	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000274	0.000373	CcSEcCtD
Glycopyrrolate—Somnolence—Docetaxel—prostate cancer	0.000272	0.000371	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Etoposide—prostate cancer	0.000272	0.00037	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—prostate cancer	0.00027	0.000368	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—prostate cancer	0.00027	0.000368	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—prostate cancer	0.00027	0.000368	CcSEcCtD
Glycopyrrolate—Dyspepsia—Docetaxel—prostate cancer	0.00027	0.000368	CcSEcCtD
Glycopyrrolate—Insomnia—Capecitabine—prostate cancer	0.000268	0.000366	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—prostate cancer	0.000268	0.000365	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—prostate cancer	0.000266	0.000362	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000265	0.000361	CcSEcCtD
Glycopyrrolate—Asthenia—Etoposide—prostate cancer	0.000265	0.000361	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—prostate cancer	0.000265	0.000361	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Prednisone—prostate cancer	0.000264	0.00036	CcSEcCtD
Glycopyrrolate—Oedema—Prednisone—prostate cancer	0.000264	0.00036	CcSEcCtD
Glycopyrrolate—Fatigue—Docetaxel—prostate cancer	0.000264	0.00036	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—prostate cancer	0.000264	0.00036	CcSEcCtD
Glycopyrrolate—Nausea—Mitoxantrone—prostate cancer	0.000263	0.000359	CcSEcCtD
Glycopyrrolate—Infection—Prednisone—prostate cancer	0.000263	0.000358	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—prostate cancer	0.000262	0.000357	CcSEcCtD
Glycopyrrolate—Constipation—Docetaxel—prostate cancer	0.000262	0.000357	CcSEcCtD
Glycopyrrolate—Pain—Docetaxel—prostate cancer	0.000262	0.000357	CcSEcCtD
Glycopyrrolate—Dyspepsia—Capecitabine—prostate cancer	0.000261	0.000356	CcSEcCtD
Glycopyrrolate—Pruritus—Etoposide—prostate cancer	0.000261	0.000356	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Prednisone—prostate cancer	0.000259	0.000353	CcSEcCtD
Glycopyrrolate—Tachycardia—Prednisone—prostate cancer	0.000258	0.000352	CcSEcCtD
Glycopyrrolate—Skin disorder—Prednisone—prostate cancer	0.000257	0.00035	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000256	0.000349	CcSEcCtD
Glycopyrrolate—Fatigue—Capecitabine—prostate cancer	0.000256	0.000349	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Prednisone—prostate cancer	0.000256	0.000348	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—prostate cancer	0.000255	0.000347	CcSEcCtD
Glycopyrrolate—Constipation—Capecitabine—prostate cancer	0.000254	0.000346	CcSEcCtD
Glycopyrrolate—Pain—Capecitabine—prostate cancer	0.000254	0.000346	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—prostate cancer	0.000253	0.000345	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—prostate cancer	0.000253	0.000345	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Docetaxel—prostate cancer	0.000253	0.000344	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Docetaxel—prostate cancer	0.000251	0.000342	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—prostate cancer	0.00025	0.000341	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—prostate cancer	0.00025	0.000341	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—prostate cancer	0.00025	0.00034	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—prostate cancer	0.000249	0.000339	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—prostate cancer	0.000248	0.000338	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—prostate cancer	0.000246	0.000335	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Capecitabine—prostate cancer	0.000245	0.000333	CcSEcCtD
Glycopyrrolate—Dizziness—Etoposide—prostate cancer	0.000244	0.000332	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Capecitabine—prostate cancer	0.000243	0.000331	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—prostate cancer	0.000243	0.000331	CcSEcCtD
Glycopyrrolate—Body temperature increased—Docetaxel—prostate cancer	0.000242	0.00033	CcSEcCtD
Glycopyrrolate—Abdominal pain—Docetaxel—prostate cancer	0.000242	0.00033	CcSEcCtD
Glycopyrrolate—Insomnia—Prednisone—prostate cancer	0.000239	0.000326	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—prostate cancer	0.000239	0.000325	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—prostate cancer	0.000236	0.000321	CcSEcCtD
Glycopyrrolate—Urticaria—Capecitabine—prostate cancer	0.000236	0.000321	CcSEcCtD
Glycopyrrolate—Body temperature increased—Capecitabine—prostate cancer	0.000235	0.00032	CcSEcCtD
Glycopyrrolate—Abdominal pain—Capecitabine—prostate cancer	0.000235	0.00032	CcSEcCtD
Glycopyrrolate—Vomiting—Etoposide—prostate cancer	0.000235	0.00032	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—prostate cancer	0.000234	0.000319	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—prostate cancer	0.000234	0.000319	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—prostate cancer	0.000233	0.000317	CcSEcCtD
Glycopyrrolate—Dyspepsia—Prednisone—prostate cancer	0.000233	0.000317	CcSEcCtD
Glycopyrrolate—Rash—Etoposide—prostate cancer	0.000233	0.000317	CcSEcCtD
Glycopyrrolate—Dermatitis—Etoposide—prostate cancer	0.000232	0.000317	CcSEcCtD
Glycopyrrolate—Headache—Etoposide—prostate cancer	0.000231	0.000315	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—prostate cancer	0.000231	0.000315	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—prostate cancer	0.00023	0.000313	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—prostate cancer	0.00023	0.000313	CcSEcCtD
Glycopyrrolate—Fatigue—Prednisone—prostate cancer	0.000228	0.000311	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—prostate cancer	0.000228	0.00031	CcSEcCtD
Glycopyrrolate—Constipation—Prednisone—prostate cancer	0.000226	0.000308	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Docetaxel—prostate cancer	0.000226	0.000308	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—prostate cancer	0.000224	0.000305	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—prostate cancer	0.000221	0.000301	CcSEcCtD
Glycopyrrolate—Asthenia—Docetaxel—prostate cancer	0.00022	0.0003	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—prostate cancer	0.000219	0.000299	CcSEcCtD
Glycopyrrolate—Nausea—Etoposide—prostate cancer	0.000219	0.000299	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—prostate cancer	0.000219	0.000298	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Capecitabine—prostate cancer	0.000219	0.000298	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Prednisone—prostate cancer	0.000218	0.000297	CcSEcCtD
Glycopyrrolate—Pruritus—Docetaxel—prostate cancer	0.000217	0.000295	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Prednisone—prostate cancer	0.000216	0.000295	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—prostate cancer	0.000215	0.000294	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000214	0.000292	CcSEcCtD
Glycopyrrolate—Asthenia—Capecitabine—prostate cancer	0.000213	0.00029	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—prostate cancer	0.000211	0.000287	CcSEcCtD
Glycopyrrolate—Urticaria—Prednisone—prostate cancer	0.00021	0.000286	CcSEcCtD
Glycopyrrolate—Pruritus—Capecitabine—prostate cancer	0.00021	0.000286	CcSEcCtD
Glycopyrrolate—Abdominal pain—Prednisone—prostate cancer	0.000209	0.000285	CcSEcCtD
Glycopyrrolate—Body temperature increased—Prednisone—prostate cancer	0.000209	0.000285	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—prostate cancer	0.000208	0.000284	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—prostate cancer	0.000207	0.000282	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—prostate cancer	0.000207	0.000282	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—prostate cancer	0.000207	0.000282	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—prostate cancer	0.000205	0.00028	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—prostate cancer	0.000203	0.000277	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—prostate cancer	0.000203	0.000276	CcSEcCtD
Glycopyrrolate—Dizziness—Docetaxel—prostate cancer	0.000203	0.000276	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—prostate cancer	0.000202	0.000276	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—prostate cancer	0.000202	0.000275	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—prostate cancer	0.000201	0.000274	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—prostate cancer	0.0002	0.000272	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000198	0.00027	CcSEcCtD
Glycopyrrolate—Dizziness—Capecitabine—prostate cancer	0.000196	0.000267	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—prostate cancer	0.000195	0.000266	CcSEcCtD
Glycopyrrolate—Vomiting—Docetaxel—prostate cancer	0.000195	0.000266	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Prednisone—prostate cancer	0.000195	0.000265	CcSEcCtD
Glycopyrrolate—Rash—Docetaxel—prostate cancer	0.000193	0.000263	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—prostate cancer	0.000193	0.000263	CcSEcCtD
Glycopyrrolate—Dermatitis—Docetaxel—prostate cancer	0.000193	0.000263	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—prostate cancer	0.000193	0.000263	CcSEcCtD
Glycopyrrolate—Headache—Docetaxel—prostate cancer	0.000192	0.000262	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—prostate cancer	0.000191	0.000261	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—prostate cancer	0.000191	0.000261	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—prostate cancer	0.00019	0.000259	CcSEcCtD
Glycopyrrolate—Asthenia—Prednisone—prostate cancer	0.00019	0.000258	CcSEcCtD
Glycopyrrolate—Vomiting—Capecitabine—prostate cancer	0.000189	0.000257	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—prostate cancer	0.000188	0.000256	CcSEcCtD
Glycopyrrolate—Rash—Capecitabine—prostate cancer	0.000187	0.000255	CcSEcCtD
Glycopyrrolate—Pruritus—Prednisone—prostate cancer	0.000187	0.000255	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—prostate cancer	0.000187	0.000255	CcSEcCtD
Glycopyrrolate—Dermatitis—Capecitabine—prostate cancer	0.000187	0.000255	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—prostate cancer	0.000187	0.000254	CcSEcCtD
Glycopyrrolate—Headache—Capecitabine—prostate cancer	0.000186	0.000253	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—prostate cancer	0.000186	0.000253	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—prostate cancer	0.000185	0.000252	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—prostate cancer	0.000184	0.00025	CcSEcCtD
Glycopyrrolate—Nausea—Docetaxel—prostate cancer	0.000182	0.000248	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—prostate cancer	0.000182	0.000248	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—prostate cancer	0.000179	0.000244	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000178	0.000243	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—prostate cancer	0.000178	0.000243	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—prostate cancer	0.000177	0.000241	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—prostate cancer	0.000177	0.000241	CcSEcCtD
Glycopyrrolate—Nausea—Capecitabine—prostate cancer	0.000176	0.00024	CcSEcCtD
Glycopyrrolate—Dizziness—Prednisone—prostate cancer	0.000175	0.000238	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—prostate cancer	0.000173	0.000236	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—prostate cancer	0.00017	0.000232	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—prostate cancer	0.00017	0.000232	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—prostate cancer	0.000169	0.00023	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—prostate cancer	0.000168	0.000229	CcSEcCtD
Glycopyrrolate—Vomiting—Prednisone—prostate cancer	0.000168	0.000229	CcSEcCtD
Glycopyrrolate—Rash—Prednisone—prostate cancer	0.000167	0.000227	CcSEcCtD
Glycopyrrolate—Dermatitis—Prednisone—prostate cancer	0.000167	0.000227	CcSEcCtD
Glycopyrrolate—Headache—Prednisone—prostate cancer	0.000166	0.000226	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000165	0.000225	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—prostate cancer	0.000165	0.000225	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—prostate cancer	0.000164	0.000224	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—prostate cancer	0.000164	0.000223	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—prostate cancer	0.000164	0.000223	CcSEcCtD
Glycopyrrolate—Oxybutynin—CYP3A4—prostate cancer	0.000164	0.302	CrCbGaD
Glycopyrrolate—Body temperature increased—Epirubicin—prostate cancer	0.000163	0.000223	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—prostate cancer	0.000163	0.000223	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—prostate cancer	0.000158	0.000215	CcSEcCtD
Glycopyrrolate—Nausea—Prednisone—prostate cancer	0.000157	0.000214	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000156	0.000213	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—prostate cancer	0.000152	0.000208	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—prostate cancer	0.000152	0.000207	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—prostate cancer	0.000151	0.000206	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—prostate cancer	0.000151	0.000206	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—prostate cancer	0.000148	0.000202	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—prostate cancer	0.000146	0.000199	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—prostate cancer	0.000141	0.000192	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—prostate cancer	0.000137	0.000187	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—prostate cancer	0.000137	0.000186	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—prostate cancer	0.000135	0.000184	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—prostate cancer	0.000131	0.000179	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—prostate cancer	0.00013	0.000178	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—prostate cancer	0.00013	0.000177	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—prostate cancer	0.00013	0.000176	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—prostate cancer	0.000127	0.000172	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—prostate cancer	0.000123	0.000167	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—prostate cancer	0.000122	0.000166	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—prostate cancer	0.000121	0.000164	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—prostate cancer	0.000121	0.000164	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—prostate cancer	0.00012	0.000163	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—prostate cancer	0.000114	0.000155	CcSEcCtD
Glycopyrrolate—CHRM1—Signaling Pathways—ITGB3—prostate cancer	2.3e-05	0.000127	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—KRAS—prostate cancer	2.3e-05	0.000127	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ITGB3—prostate cancer	2.29e-05	0.000127	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ITGB3—prostate cancer	2.27e-05	0.000126	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAP2K1—prostate cancer	2.27e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CD—prostate cancer	2.25e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—FGF2—prostate cancer	2.25e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	2.25e-05	0.000124	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	2.24e-05	0.000124	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ERBB3—prostate cancer	2.23e-05	0.000124	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—PIK3CA—prostate cancer	2.23e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FGFR2—prostate cancer	2.23e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—SERPINE1—prostate cancer	2.23e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ERBB3—prostate cancer	2.23e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FGFR2—prostate cancer	2.22e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—NOS3—prostate cancer	2.22e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	2.22e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ERBB3—prostate cancer	2.2e-05	0.000122	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—KRAS—prostate cancer	2.2e-05	0.000122	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FGFR2—prostate cancer	2.2e-05	0.000122	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—JAK2—prostate cancer	2.16e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—FGF2—prostate cancer	2.16e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CG—prostate cancer	2.15e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL2—prostate cancer	2.15e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL2—prostate cancer	2.14e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TERT—prostate cancer	2.14e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TERT—prostate cancer	2.13e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—NOS3—prostate cancer	2.13e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL2—prostate cancer	2.12e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—PIK3CA—prostate cancer	2.11e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TERT—prostate cancer	2.11e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MDM2—prostate cancer	2.11e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—ERBB2—prostate cancer	2.08e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—JAK2—prostate cancer	2.07e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CB—prostate cancer	2.05e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HIF1A—prostate cancer	2.05e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HIF1A—prostate cancer	2.04e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—INS—prostate cancer	2.03e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—PIK3CA—prostate cancer	2.02e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.02e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MDM2—prostate cancer	2.02e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—LEP—prostate cancer	2e-05	0.000111	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—CREBBP—prostate cancer	1.99e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—LEP—prostate cancer	1.99e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—ERBB2—prostate cancer	1.99e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CAV1—prostate cancer	1.98e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CAV1—prostate cancer	1.97e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—LEP—prostate cancer	1.97e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CXCL8—prostate cancer	1.97e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CB—prostate cancer	1.96e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KDR—prostate cancer	1.96e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CAV1—prostate cancer	1.95e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KDR—prostate cancer	1.95e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KDR—prostate cancer	1.93e-05	0.000107	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1B—prostate cancer	1.92e-05	0.000106	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ESR1—prostate cancer	1.91e-05	0.000106	CbGpPWpGaD
Glycopyrrolate—CHRM4—GPCR downstream signaling—AKT1—prostate cancer	1.9e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ESR1—prostate cancer	1.9e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CD—prostate cancer	1.89e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CXCL8—prostate cancer	1.89e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CASP3—prostate cancer	1.88e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ESR1—prostate cancer	1.88e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL2—prostate cancer	1.88e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—IL6—prostate cancer	1.87e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—BAD—prostate cancer	1.86e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—BAD—prostate cancer	1.86e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1B—prostate cancer	1.84e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—BAD—prostate cancer	1.84e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CCND1—prostate cancer	1.83e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—AKT1—prostate cancer	1.82e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CTNNB1—prostate cancer	1.82e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CASP3—prostate cancer	1.8e-05	9.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	1.8e-05	9.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APC—prostate cancer	1.8e-05	9.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL2—prostate cancer	1.8e-05	9.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	1.8e-05	9.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APC—prostate cancer	1.8e-05	9.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—IL6—prostate cancer	1.79e-05	9.92e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—NOS3—prostate cancer	1.78e-05	9.88e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGF—prostate cancer	1.78e-05	9.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IRS1—prostate cancer	1.78e-05	9.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MMP9—prostate cancer	1.78e-05	9.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APC—prostate cancer	1.78e-05	9.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	1.78e-05	9.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IRS1—prostate cancer	1.78e-05	9.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGF—prostate cancer	1.78e-05	9.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	1.77e-05	9.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PTEN—prostate cancer	1.77e-05	9.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGF—prostate cancer	1.76e-05	9.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IRS1—prostate cancer	1.76e-05	9.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CCND1—prostate cancer	1.76e-05	9.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	1.74e-05	9.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—GSK3B—prostate cancer	1.73e-05	9.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—AKT1—prostate cancer	1.73e-05	9.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—GSK3B—prostate cancer	1.72e-05	9.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—GSK3B—prostate cancer	1.71e-05	9.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—INS—prostate cancer	1.71e-05	9.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MMP9—prostate cancer	1.71e-05	9.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—INS—prostate cancer	1.7e-05	9.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	1.7e-05	9.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PTEN—prostate cancer	1.7e-05	9.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—EP300—prostate cancer	1.69e-05	9.35e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—INS—prostate cancer	1.68e-05	9.32e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CREBBP—prostate cancer	1.67e-05	9.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CREBBP—prostate cancer	1.67e-05	9.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—AKT1—prostate cancer	1.65e-05	9.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IGF1—prostate cancer	1.65e-05	9.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CREBBP—prostate cancer	1.65e-05	9.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CB—prostate cancer	1.65e-05	9.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IGF1—prostate cancer	1.65e-05	9.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—EGFR—prostate cancer	1.64e-05	9.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—SRC—prostate cancer	1.64e-05	9.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—EGFR—prostate cancer	1.64e-05	9.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTGS2—prostate cancer	1.63e-05	9.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IGF1—prostate cancer	1.63e-05	9.02e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—EGFR—prostate cancer	1.62e-05	8.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—EP300—prostate cancer	1.62e-05	8.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—VEGFA—prostate cancer	1.6e-05	8.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.6e-05	8.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	1.59e-05	8.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.58e-05	8.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—STAT3—prostate cancer	1.58e-05	8.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	1.58e-05	8.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	1.57e-05	8.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—SRC—prostate cancer	1.57e-05	8.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.57e-05	8.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.57e-05	8.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	1.56e-05	8.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	1.56e-05	8.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	1.56e-05	8.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.55e-05	8.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	1.55e-05	8.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	1.55e-05	8.57e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—KRAS—prostate cancer	1.55e-05	8.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—KRAS—prostate cancer	1.53e-05	8.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—VEGFA—prostate cancer	1.53e-05	8.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.52e-05	8.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—STAT3—prostate cancer	1.52e-05	8.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FGF2—prostate cancer	1.51e-05	8.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FGF2—prostate cancer	1.5e-05	8.29e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.5e-05	8.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NOS3—prostate cancer	1.49e-05	8.26e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NOS3—prostate cancer	1.48e-05	8.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MYC—prostate cancer	1.47e-05	8.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TGFB1—prostate cancer	1.47e-05	8.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.45e-05	8.05e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—JAK2—prostate cancer	1.45e-05	8.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—EGFR—prostate cancer	1.44e-05	7.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—JAK2—prostate cancer	1.44e-05	7.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.43e-05	7.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTEN—prostate cancer	1.42e-05	7.88e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	1.42e-05	7.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.42e-05	7.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MDM2—prostate cancer	1.42e-05	7.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MYC—prostate cancer	1.41e-05	7.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	1.41e-05	7.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TGFB1—prostate cancer	1.41e-05	7.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MDM2—prostate cancer	1.4e-05	7.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.4e-05	7.75e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ERBB2—prostate cancer	1.4e-05	7.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.38e-05	7.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.38e-05	7.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—EGFR—prostate cancer	1.38e-05	7.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	1.38e-05	7.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.36e-05	7.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—KRAS—prostate cancer	1.36e-05	7.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—EP300—prostate cancer	1.36e-05	7.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.33e-05	7.35e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CXCL8—prostate cancer	1.32e-05	7.32e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.31e-05	7.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—KRAS—prostate cancer	1.3e-05	7.21e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.3e-05	7.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	1.29e-05	7.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.28e-05	7.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.28e-05	7.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	1.28e-05	7.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.27e-05	7.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL2—prostate cancer	1.27e-05	7.02e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CASP3—prostate cancer	1.27e-05	7.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.27e-05	7.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL2—prostate cancer	1.26e-05	7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.26e-05	6.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL6—prostate cancer	1.26e-05	6.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.25e-05	6.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL2—prostate cancer	1.25e-05	6.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	1.25e-05	6.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.25e-05	6.9e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.24e-05	6.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CCND1—prostate cancer	1.23e-05	6.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.22e-05	6.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.22e-05	6.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	1.22e-05	6.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.21e-05	6.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TP53—prostate cancer	1.21e-05	6.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.2e-05	6.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.2e-05	6.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.2e-05	6.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	1.2e-05	6.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.19e-05	6.61e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.19e-05	6.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.19e-05	6.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.19e-05	6.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.18e-05	6.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.18e-05	6.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.16e-05	6.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.16e-05	6.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TP53—prostate cancer	1.16e-05	6.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.15e-05	6.36e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EP300—prostate cancer	1.14e-05	6.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EP300—prostate cancer	1.13e-05	6.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EP300—prostate cancer	1.12e-05	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SRC—prostate cancer	1.11e-05	6.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL6—prostate cancer	1.11e-05	6.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SRC—prostate cancer	1.1e-05	6.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SRC—prostate cancer	1.09e-05	6.05e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.08e-05	5.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.07e-05	5.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.07e-05	5.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.06e-05	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.06e-05	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL6—prostate cancer	1.06e-05	5.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.05e-05	5.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—AKT1—prostate cancer	1.02e-05	5.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CA—prostate cancer	1e-05	5.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MYC—prostate cancer	9.92e-06	5.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TGFB1—prostate cancer	9.9e-06	5.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MYC—prostate cancer	9.89e-06	5.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TGFB1—prostate cancer	9.86e-06	5.46e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MYC—prostate cancer	9.79e-06	5.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—AKT1—prostate cancer	9.77e-06	5.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TGFB1—prostate cancer	9.77e-06	5.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGFR—prostate cancer	9.7e-06	5.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGFR—prostate cancer	9.67e-06	5.35e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGFR—prostate cancer	9.58e-06	5.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KRAS—prostate cancer	9.17e-06	5.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KRAS—prostate cancer	9.14e-06	5.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KRAS—prostate cancer	9.05e-06	5.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	8.42e-06	4.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	8.39e-06	4.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	8.31e-06	4.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—AKT1—prostate cancer	8.2e-06	4.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TP53—prostate cancer	8.15e-06	4.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TP53—prostate cancer	8.12e-06	4.5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TP53—prostate cancer	8.04e-06	4.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL6—prostate cancer	7.46e-06	4.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL6—prostate cancer	7.43e-06	4.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL6—prostate cancer	7.36e-06	4.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT1—prostate cancer	6.88e-06	3.81e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT1—prostate cancer	6.86e-06	3.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT1—prostate cancer	6.79e-06	3.76e-05	CbGpPWpGaD
